• Explore /
  • Poster
  • / The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM).

The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM).

Abstract Poster

Authors

null

Samer Tabchi

The University of Texas MD Anderson Cancer Center, Houston, TX

Samer Tabchi , Ranjit Nair , Krina K. Patel , Hans Chulhee Lee , Sheeba K. Thomas , Behrang Amini , Sairah Ahmed , Rohtesh S. Mehta , Qaiser Bashir , Muzaffar H. Qazilbash , Donna M. Weber , Robert Z. Orlowski , Raymond Alexanian , Lei Feng , Elisabet Esteve Manasanch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8044)

DOI

10.1200/JCO.2018.36.15_suppl.8044

Abstract #

8044

Poster Bd #

53

Abstract Disclosures

Similar Posters

First Author: Cyrille Touzeau

First Author: Robert M. Rifkin

First Author: Saad Z. Usmani

First Author: David Siegel